title: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
authors.affiliation: Division of Hematology-Oncology, The Ohio State University, Columbus, Ohio 43210, USA. shah-2@medctr.osu.edu
authors.forename: Manisha H
authors.initials: MH
authors.lastname: Shah
authors.forename: Donn
authors.initials: D
authors.lastname: Young
authors.forename: Hedy L
authors.initials: HL
authors.lastname: Kindler
authors.forename: Iain
authors.initials: I
authors.lastname: Webb
authors.forename: Barbara
authors.initials: B
authors.lastname: Kleiber
authors.forename: John
authors.initials: J
authors.lastname: Wright
authors.forename: Michael
authors.initials: M
authors.lastname: Grever
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002276:Carcinoid Tumor / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib